Ron Bose
YOU?
Author Swipe
View article: The TROP2 targeting antibody-drug conjugate IMMU-132 enhances the efficacy of radiation therapy for lung cancer
The TROP2 targeting antibody-drug conjugate IMMU-132 enhances the efficacy of radiation therapy for lung cancer Open
Studies suggest that the human trophoblast cell-surface antigen (TROP2) is highly expressed in most lung cancers and is associated with poor prognosis. Currently, there are no TROP2-directed ADCs approved for treating lung cancer patients.…
View article: PRCA-04 TARGETING A UNIQUE ACTIVATION RECEPTOR COMPLEX TO TREAT INTRACRANIAL BREAST CARCINOMA.
PRCA-04 TARGETING A UNIQUE ACTIVATION RECEPTOR COMPLEX TO TREAT INTRACRANIAL BREAST CARCINOMA. Open
Despite enhanced therapies against primary breast carcinoma (BC), intracranial metastases remain incurable and are associated with a decreased quality of life. To address this unmet medical need, we developed a new therapy (ARL200CNS), rep…
View article: Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose:A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associatio…
View article: Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 1
View article: Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 2
View article: Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 2
View article: Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 3
View article: Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 1
View article: Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 4
View article: HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan Open
In metastatic breast cancer, HER2 -activating mutations often co-occur with TP53 mutations, a combination linked to poor response to neratinib and worse prognosis. To model this clinical challenge, we bred HER2 V777L transgenic mice with t…
View article: Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages Open
SUMMARY Brain metastases occur in up to 40% of Stage IV breast cancer patients. The cerebellum is a frequent location for metastases in HER2-positive breast cancer patients, but the mechanisms for this are unknown. Here, we developed a syn…
View article: ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose: A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associati…
View article: Data from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Data from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Purpose:Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. Although molecular residual disease assays show promise, their use in the neoadjuvant setting req…
View article: Supplementary Data 1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Supplementary Data 1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Supplementary Figures S1-S5
View article: Supplemental Table S1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Supplemental Table S1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Details of patient-level evaluable samples
View article: Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer Open
HER2 is a membrane receptor tyrosine kinase overexpressed in 18-20% of gastric tumors. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that targets HER2-positive (HER2+) cancer cells with a chemotherapeutic agent, emtansi…
View article: Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Purpose: Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. Although molecular residual disease assays show promise, their use in the neoadjuvant setting re…
View article: The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and Fulvestrant in HER2-Mutated Breast Cancer
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and Fulvestrant in HER2-Mutated Breast Cancer Open
PURPOSE: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. PATIENTS AND METHODS: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant …
View article: Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis Open
Sacituzumab has a high affinity for Trop-2 protein which is also expressed within the collecting ducts, and to a lesser extent, the proximal tubule. Individuals, such as this patient, who express a homozygous genotype for UGT1A1*28 allele …
View article: Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages Open
Breast cancer (BC) is defined by distinct molecular subtypes with different cells of origin. The transcriptional networks that characterize the subtype-specific tumor-normal lineages are not established. In this work, we applied bulk, sing…
View article: Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance. Open
Phosphopeptides in Heatmap
View article: Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance. Open
Phosphopeptides in Heatmap
View article: Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Data from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Data from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Introduction: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates (ADC). While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low…
View article: Table S1 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
Table S1 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance. Open
Phosphoproteins
View article: Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Table S2 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
Table S2 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance. Open
Phosphopeptides
View article: Table S4 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
Table S4 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance. Open
Phosphopeptides in Volcano Plot